Drugs / GACYCLIDINE
GACYCLIDINE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00957788 | Jan 2009 → May 2013 | tinnitus | NeuroSystec Corporation | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03918109 | Apr 2019 → May 2020 | tinnitus | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04829214 | Mar 2021 → Jun 2022 | tinnitus | Otonomy, Inc. | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GACYCLIDINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989791 ↗ |
| Known as | Gaciclidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989791 ↗ |
| Known as | NST-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00957788 ↗ |
| Known as | OTO-313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03918109 ↗ |
| Modality | Small molecule | — CHEMBL3989791 ↗ |
| Route | Other | “single intratympanic injection of gacyclidine” NCT03918109 ↗ |